FacebookTwitterGoogle+RedditEmail

Born With a Statin Deficiency?

by MARTHA ROSENBERG

When Dr. Paul Ridker of Brigham and Women’s Hospital in Boston, MA presented the results of the AstraZeneca-funded JUPITER study at the American Heart Association conference in November–JUPITER standing for The Justification for the Use of Statins in Primary Prevention–there were a lot more stenographers than skeptics in the press corps.

How could a drug company-funded study designed to show why the general population should use its drug (Crestor, or rosuvastatin) be objective? Or even newsworthy?

Especially when its lead author is co-inventor on the related patent?

And its authors list 131 financial ties to drug companies? Hello?

But the press didn’t let overt conflicts of interest–COIs as pharma calls them because they’re so common–ruin the story.

“AstraZeneca’s Crestor Cuts Death, Heart Attack,” exalted Reuters remembering the PR dictim of getting Name and Company in the headline. “Crestor Study Seen Changing Preventive Treatment!”

“Wider Cholesterol Drug Use May Save Lives,” trumpeted other headlines.

“Statins For Everyone!”

“Crestor In The Water?”

Was this the same Crestor which was vilified in a Lancet editorial three months after its 2003 US approval as “inadequately investigated”?

Named as one of the top five most dangerous drugs by the FDA’s Dr. David “Vioxx” Graham on Capitol Hill in 2004?

Petitioned for recall by the Washington D.C. based Public Citizen?

Found worthless against chronic heart failure just one month earlier in Lancet?

In the feeder frenzy to cover the self-engineered drug breakthrough, where was press mention of another American Heart Association finding about Crestor in its journal Circulation in 2005? [111:3051-3057]

That Crestor “was significantly more likely to be associated with the composite end point of rhabdomyolysis, proteinuria, nephropathy, or renal failure,” than other drugs?

Where was mention of the FDA warning about rhabdomyolysis–the muscle disease that did Bayer’s Baycol in–that was added to Crestor in 2005 after a patient death–along with warnings to the physician about Crestor use in Asian patients, people with severe kidney disease and patients taking cyclosporine?

Oops.

But while the gee whiz press focused on the JUPITER study’s startling results–the Crestor group had a 54 percent reduction in heart attacks, 48 percent reduction in strokes and 20 percent reduction in death compared to placebo–especially in light of the fact that the study group was free of heart disease and high cholesterol, most doctors wouldn’t drink the AstraZeneca Kool-Aid.

The study’s 17,802 enrollees may have had normal levels of the bad LDL cholesterol but some were “walking vasculopaths,” with abnormal C-reactive protein levels [CRP] which indicate inflammation in the body said Dr. Bernadine Healy, health editor for U.S. News & World Report.

“As a result, the JUPITER trial was riddled with obesity, high blood pressure, prediabetes, and genes predisposing to heart disease,” said Healy. “Almost 3,000 enrollees were smokers, a big time CRP elevator, and only 10 percent took aspirin, an inexpensive preventive medicine that protects against both heart disease and stroke. (Aspirin also lowers CRP.) Other study patients were really healthy, free of any known risk factors and yet had elevated CRP for no obvious reason.”

While the press bought AstraZeneca’s contrivance that the JUPITER study was so conclusive it was ended early, many of the 470 doctors who posted online comments after the study in the New England Journal of Medicine (Nov. 20, 2008) said you ended the trial WHEN?

“It is well established that RCTs [randomized controlled trials] stopped early overestimate benefits significantly,” wrote a physician from Rochester, MN.

“It is shocking that this trial was terminated 50% through, based on a small absolute benefit, with real questions about long term risk,” said a poster from the Public Health Law Program, LSU Law Center.

“There is no justification for stopping the follow-up, even if the triallists felt it was unethical to recruit new patients,” wrote a physician from Yorkshire, UK. “Congratulations to AstraZeneca for selling the results to the uncritical lay media. I feel sorry for all the family doctors who will be pestered by patients for some time to come.”

Doctors also balked at the study’s ipso facto preference for a pill over lifestyle changes like diet and exercise–including the well known Dr. Dean Ornish of Preventive Medicine Research Institute who noted the nation spent $20 billion on cholesterol-lowering drugs last year.

While cardiologists were soft on the study–except one who assailed the Western “pandemic food addiction and the mirage of immortality in a bottle of pills”–many other doctors detected disease mongering behind JUPITER of the sort that sold HRT and Vioxx to anyone over 50.

Even a medical student wasn’t impressed.

“I don’t think risking the patient’s life by giving him statins is a correct procedure. I would be giving him/her benefits for a disease which has not been diagnosed yet and increasing the odds of developing another disease (Diabetes),” she wrote.

MARTHA ROSENBERG is staff cartoonist on the Evanston Roundtable. She can be reached at mrosenberg@evmark.org

 

 

 

 

 

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

More articles by:

CounterPunch Magazine

minimag-edit

bernie-the-sandernistas-cover-344x550

zen economics

March 27, 2017
Robert Hunziker
A Record-Setting Climate Going Bonkers
Frank Stricker
Why $15 an Hour Should be the Absolute Minimum Minimum Wage
Melvin Goodman
The Disappearance of Bipartisanship on the Intelligence Committees
Patrick Cockburn
ISIS’s Losses in Syria and Iraq Will Make It Difficult to Recruit
Russell Mokhiber
Single-Payer Bernie Morphs Into Public Option Dean
Gregory Barrett
Can Democracy Save Us?
Dave Lindorff
Budget Goes Military
John Heid
Disappeared on the Border: “Chase and Scatter” — to Death
Mark Weisbrot
The Troubling Financial Activities of an Ecuadorian Presidential Candidate
Robert Fisk
As ISIS’s Caliphate Shrinks, Syrian Anger Grows
Michael J. Sainato
Democratic Party Continues Shunning Popular Sanders Surrogates
Paul Bentley
Nazi Heritage: the Strange Saga of Chrystia Freeland’s Ukrainian Grandfather
Christopher Ketcham
Buddhism in the Storm
Thomas Barker
Platitudes in the Wake of London’s Terror Attack
Mike Hastie
Insane Truths: a Vietnam Vet on “Apocalypse Now, Redux”
Binoy Kampmark
Cyclone Watch in Australia
Weekend Edition
March 24, 2017
Friday - Sunday
Michael Hudson
Trump is Obama’s Legacy: Will this Break up the Democratic Party?
Eric Draitser
Donald Trump and the Triumph of White Identity Politics
Jeffrey St. Clair
Roaming Charges: Nothing Was Delivered
Andrew Levine
Ryan’s Choice
Joshua Frank
Global Coal in Freefall, Tar Sands Development Drying Up (Bad News for Keystone XL)
Anthony DiMaggio
Ditching the “Deep State”: The Rise of a New Conspiracy Theory in American Politics
Rob Urie
Boris and Natasha Visit Fantasy Island
John Wight
London and the Dreary Ritual of Terrorist Attacks
Paul Buhle
The CIA and the Intellectuals…Again
David Rosen
Why Did Trump Target Transgender Youth?
Vijay Prashad
Inventing Enemies
Ben Debney
Outrage From the Imperial Playbook
M. Shadee Malaklou
An Open Letter to Duke University’s Class of 2007, About Your Open Letter to Stephen Miller
Michael J. Sainato
Bernie Sanders’ Economic Advisor Shreds Trumponomics
Lawrence Davidson
Moral Failure at the UN
Pete Dolack
World Bank Declares Itself Above the Law
Nicola Perugini - Neve Gordon
Israel’s Human Rights Spies
Patrick Cockburn
From Paris to London: Another City, Another Attack
Ralph Nader
Reason and Justice Address Realities
Ramzy Baroud
‘Decolonizing the Mind’: Using Hollywood Celebrities to Validate Islam
Colin Todhunter
Monsanto in India: The Sacred and the Profane
Louisa Willcox
Grizzlies Under the Endangered Species Act: How Have They Fared?
Norman Pollack
Militarization of American Fascism: Trump the Usurper
Pepe Escobar
North Korea: The Real Serious Options on the Table
Brian Cloughley
“These Things Are Done”: Eavesdropping on Trump
Sheldon Richman
You Can’t Blame Trump’s Military Budget on NATO
Carol Wolman
Trump vs the People: a Psychiatrist’s Analysis
Kollibri terre Sonnenblume
Marines to Kill Desert Tortoises
Stanley L. Cohen
The White House . . . Denial and Cover-ups
FacebookTwitterGoogle+RedditEmail